NF-κB
NF-κB regulates innate and adaptive immunity, inflammatory responses, immune-cell survival, activation, and differentiation[1]. Mechanistically, canonical NF-κB signaling depends on phosphorylation-induced proteasomal degradation of IκB proteins, releasing cytosolic NF-κB dimers for transcriptional control[2]. In inflammation models, NF-κB induces cytokines, chemokines, adhesion molecules, and inflammasome-related responses, linking pathway activation to chronic inflammatory disease and cancer research[1][3][4]. Compared with related isoforms, mammalian NF-κB includes RelA/p65, RelB, c-Rel, p50/NF-κB1, and p52/NF-κB2, and RelA loss causes embryonic lethality with liver apoptosis, whereas p50 loss produces immune-response defects without developmental abnormalities[2][5][6]. For experimental applications, NF-κB inhibitors, including IKK-targeting agents and BAY 11-7082, help test pathway dependence in inflammatory signaling, but broad pathway targeting requires careful interpretation because NF-κB also supports normal immune physiology[4][7].
References:
- [1]. Liu T, et al. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023–. [Content Brief]
- [2]. Oeckinghaus A, et al. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034. [Content Brief]
- [3]. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651. doi: 10.1101/cshperspect.a001651. Epub 2009 Oct 7. PMID: 20457564; PMCID: PMC2882124. et al. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651. [Content Brief]
- [4]. Yu H, et al. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020 Sep 21;5(1):209. [Content Brief]
- [5]. Beg AA, et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 1995 Jul 13;376(6536):167-70. [Content Brief]
- [6]. Sha WC, et al. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell. 1995 Jan 27;80(2):321-30. [Content Brief]
- [7]. Lee J, et al. BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. Mediators Inflamm. 2012;2012:416036. [Content Brief]
All Product Categories
-
NF-κB Inhibitors
(1212)
View all products
-
NF-κB Agonists
(4)
View all products
-
NF-κB Activators
(100)
View all products
-
NF-κB Modulators
(26)
View all products
-
NF-κB Inducers
(2)
View all products
-
NF-κB Degraders
(2)
View all products
-
NF-κB Controls
(6)
View all products
-
NF-κB Ligand
(1)
View all products
-
NF-κB Related Products (1454)
Related Products (1454)
-
Antibodies (24)
-
Colistin adjuvant-1
0 ImagesCat. No.: HY-145439CAS No.: 2862800-15-3
-
Pellitorine (Standard)
0 ImagesCat. No.: HY-N3097RCAS No.: 18836-52-7Pellitorine (Standard) is the analytical standard of Pellitorine (HY-N3097). Pellitorine is a bioactive natural amide compound. Pellitorine can competitively antagonize the activation of TRPV1 by Capsaicin (HY-10448), thereby reducing pain signal transmission. Pellitorine improves cognitive dysfunction by upregulating the BDNF-ERK1/2-CREB and Nrf2-HO-1 pathways. Pellitorine exerts anti-inflammatory and anti-sepsis effects by inhibiting the release of high mobility group protein B1 (HMGB1) and the expression of RAGE/TLR4. Pellitorine exerts its antithrombotic effect by prolonging the clotting time, inhibiting the activity of clotting factors and thrombin. Pellitorine inhibits lipid peroxidation and resists ferroptosis by upregulating GPX4 and DHODH. Pellitorine kills Aedes aegypti mosquito larvae by inhibiting V-type H⁺-ATPase and aquaporin 4 (AaAQP4). Pellitorine exhibits anti-cancer activity (e.g., leukemia and breast cancer) and has inhibitory effects on certain bacteria.
-
(−)-N-Hydroxyapiosporamide
0 ImagesCat. No.: HY-N11777CAS No.: 1205676-02-3Synonyms: NHAP(−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an NF-κB inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC).
-
Swertiamarin (Standard)
0 ImagesCat. No.: HY-N0807RCAS No.: 17388-39-5Swertiamarin (Standard) is the analytical standard of Swertiamarin. This product is intended for research and analytical applications. Swertiamarin is an orally active iridoid compound with hypoglycemic, hypolipidemic, anti rheumatic and antioxidant activities, which can be used in the research of diabetes and arthritis.
-
α-Lipoic Acid sodium (Standard)
0 ImagesSynonyms: Thioctic acid sodium (Standard); (±)-α-Lipoic acid sodium (Standard); DL-α-Lipoic acid sodium (Standard)α-Lipoic Acid (sodium) (Standard) is the analytical standard of α-Lipoic Acid (sodium). This product is intended for research and analytical applications. α-Lipoic Acid (Thioctic acid) sodium is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid sodium inhibits NF-κB-dependent HIV-1 LTR activation. α-Lipoic Acid sodium induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells. α-Lipoic Acid sodium can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1.
-
Rela Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS11828Rela Rat Pre-designed siRNA Set A contains three designed siRNAs for Rela gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
TLR4/NF-κB/MAPK-IN-1
0 ImagesCat. No.: HY-142963CAS No.: 2767567-26-8TLR4/NF-κB/MAPK-IN-1 is a new type of antineuroinflammatory agent by suppressing TLR4/NF-kB/MAPK pathways.
-
SMU-C409
0 ImagesCat. No.: HY-180580CAS No.: 3113739-61-7SMU-C409 is a TLR1/2 agonist with an EC50 of 65 nM in HEK-Blue hTLR2 Cells. SMU-C409 activates the TLR1/2–MyD88–NF-κB pathway, inducing TNF-α/IL-1β secretion and robust immune cell activation for antitumor immunomodulation. SMU-C409 shows low toxicity in virto. SMU-C409 can be used for cancer immunotherapy research.
-
TNF-α-IN-28
0 ImagesCat. No.: HY-182006CAS No.: 3118012-34-0
-
Nalmefene-d4
0 ImagesCat. No.: HY-142570S1Nalmefene-d4 is the deuterium labeled Nalmefene (HY-107744). Nalmefene is a BBB-penetrable?opioid receptor?modulator. Nalmefene is an antagonist of?MOR?and?DOR, and a partial agonist of?KOR. Nalmefene has anti-inflammatory and neuroprotective activities. Nalmefene can be used in the research of reducing alcohol-dependent disorders.
-
Moniliphenone
0 ImagesCat. No.: HY-W971442CAS No.: 104022-80-2Moniliphenone (Compounds 5) is a secondary metabolite. Moniliphenone can be isolated from the endophytic fungus Penicillium chrysogenum. Moniliphenone has an anti-inflammatory activity and significantly inhibits TNF-α-stimulated NF-κB activation.
-
Antidesmone
0 ImagesCat. No.: HY-119731CAS No.: 222629-77-8Antidesmone is a isoquinoline alkaloid that can be isolated from Antidesma membranaceum. Antidesmone can prevent acute lung injury in vivo via inhibiting MAPK and NF-κb activities.
-
Bortezomib (GMP)
0 ImagesCat. No.: HY-10227GSynonyms: PS-341 (GMP); LDP-341 (GMP); NSC 681239 (GMP)Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
-
NF-κB-IN-2
0 ImagesCat. No.: HY-142958CAS No.: 1821386-63-3NF-κB-IN-2 inhibits TNF-α-induced canonical NF-κB signaling in PC-3 cells.
-
Apoptosis/necroptosis inducer 1
0 ImagesCat. No.: HY-181073Apoptosis/necroptosis inducer 1 is an orally active and brain-penetrant apoptosis and necroptosis inducer. Apoptosis/necroptosis inducer 1 induces mitochondria-dependent (intrinsic pathway) apoptosis. Apoptosis/necroptosis inducer 1 induces necroptosis by activating the TNF-α/NF-κB/MAPK signaling pathway. Apoptosis/necroptosis inducer 1 exhibits antiproliferative activity in glioblastoma cell lines and multiple solid tumor types. Apoptosis/necroptosis inducer 1 inhibits growth of orthotopic glioblastoma in animal models and improves survival rate. Apoptosis/necroptosis inducer 1 can be used for the research of glioblastoma.
-
Cynaropicrin (Standard)
0 ImagesCat. No.: HY-N2350RCAS No.: 35730-78-0Cynaropicrin (Standard) is the analytical standard of Cynaropicrin. This product is intended for research and analytical applications. Cynaropicrin is a sesquiterpene lactone which can inhibit tumor necrosis factor (TNF-α) release with IC50s of 8.24 and 3.18 μM for murine and human macrophage cells, respectively. Cynaropicrin also inhibits the increase of cartilage degradation factor (MMP13) and suppresses NF-κB signaling.
-
Hentriacontane (Standard)
0 ImagesHentriacontane (Standard) is the analytical standard of Hentriacontane. This product is intended for research and analytical applications. Hentriacontane is a long-chain alkane. Hentriacontane exerts anti-inflammatory effects by inhibiting the NF-κB pathway. Hentriacontane has anti-inflammatory, antitumor and antibacterial activities.
-
IR-Crizotinib
0 ImagesCat. No.: HY-149696CAS No.: 2387927-74-2IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC50=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research.
-
ABD56
0 ImagesCat. No.: HY-122019CAS No.: 521294-19-9
